ライフサイエンスコーパス: bombesin

1 involved in interactions with the agonist dY-bombesin.

2 LPA and that LPA production is increased by bombesin.

3 dominant-negative Etk/BMX fail to respond to bombesin.

4 ular reticular nuclei were not responsive to bombesin.

5 534 phosphorylation induced by EGF, IL-6 and bombesin.

6 D, (64)Cu-NOTA-bombesin, and (64)Cu-DOTA-RGD-bombesin.

7 r tissue, which had no uptake of (64)Cu-NOTA-bombesin.

8 -activating protein (20 pmol/L, >8-fold) and bombesin (0.1 micromol/L, 8-fold) through cAMP signaling

9 Bombesin (0.2, 0.6 or 6.2 pmol) microinjected into the v

10 ls stimulated with various concentrations of bombesin (0.3-10 nm) or with vasopressin, a different G(

11 receptor antagonist, [D-Phe(6), Leu-NHEt(13)]bombesin (6-13).

12 Bombesin (6.2 pmol) injected into the dorsal motor nucle

13 3]Bombesin ([Lys3]BBN) and aminocaproic acid-bombesin(7-14) (Aca-BBN(7-14)) were labeled with 18F by

14 studies demonstrate that (64)Cu-SarAr-SA-Aoc-bombesin(7-14) and (64)Cu-SarAr-SA-Aoc-GSG-bombesin(7-14

15 jected dose per gram for (64)Cu-SarAr-SA-Aoc-bombesin(7-14) and (64)Cu-SarAr-SA-Aoc-GSG-bombesin(7-14

16 nalog (15.1 vs. 11.3 for (64)Cu-SarAr-SA-Aoc-bombesin(7-14) and (64)Cu-SarAr-SA-Aoc-GSG-bombesin(7-14

17 A BBN-RGD heterodimer was synthesized from bombesin(7-14) and c(RGDyK) through a glutamate linker a

18 ng assay demonstrated that both SarAr-SA-Aoc-bombesin(7-14) and SarAr-SA-Aoc-GSG-bombesin(7-14) bound

19 in(7-14) to yield the resulting SarAr-SA-Aoc-bombesin(7-14) and SarAr-SA-Aoc-GSG-bombesin(7-14) pepti

20 r-SA-Aoc-bombesin(7-14) and SarAr-SA-Aoc-GSG-bombesin(7-14) bound with high affinity to GRPR with an

21 c-bombesin(7-14) and (64)Cu-SarAr-SA-Aoc-GSG-bombesin(7-14) bound with high affinity to GRPR-expressi

22 ed as previously published and conjugated to bombesin(7-14) by solid-phase peptide synthesis using st

23 onjugated to the 8 C-terminal amino acids of bombesin(7-14) for radiolabeling with (64)Cu.

24 The (64)Cu-SarAr-SA-Aoc-GSG-bombesin(7-14) had more rapid blood clearance and lower

25 r-SA-Aoc-bombesin(7-14) and SarAr-SA-Aoc-GSG-bombesin(7-14) peptides.

26 (GSG) were used as linkers between SarAr and bombesin(7-14) to yield the resulting SarAr-SA-Aoc-bombe

27 6]-eicosane-1,8-diamine) (SarAr) chelator to bombesin(7-14), radiolabel the conjugate with (64)Cu, an

28 c-bombesin(7-14) and (64)Cu-SarAr-SA-Aoc-GSG-bombesin(7-14), respectively, at 1 h) and imaging that w

29 c-bombesin(7-14) and (64)Cu-SarAr-SA-Aoc-GSG-bombesin(7-14), respectively, at 1 h).

30 ormal-tissue uptake than (64)Cu-SarAr-SA-Aoc-bombesin(7-14), resulting in similar tumor-to-blood rati

31 oblasts and epithelial cells stimulated with bombesin, a GPCR agonist.

32 We report that bombesin, a homolog of GRP, potently stimulates the expr

33 Bombesin, a neuroendocrine peptide that is mitogenic for

34 Bombesin action in the VLRF was long lasting (96% inhibi

35 We show that bombesin-activated AR (a) is required for bombesin-induc

36 ptide, dY-Q-W-A-V-(beta-A)-H-F-Nle-amide (dY-bombesin), activates human BRS-3 with an EC(50) of 1.2 n

37 These results indicate that bombesin acts in the VLRF to inhibit pentagastrin-stimul

38 Sites in the medulla oblongata where bombesin acts to suppress gastric acid secretion were in

39 Stimulation of Swiss 3T3 cells with bombesin also induced a rapid increase in the phosphoryl

40 (64)Cu-NOTA-RGD-bombesin also outperformed (64)Cu-NOTA-RGD in a 4T1 muri

41 (64)Cu-NOTA-RGD-bombesin also showed improved in vivo kinetics such as l

42 Targeted cytotoxic analogs of bombesin (AN-215), somatostatin (AN-238), and luteinizin

43 The NOTA-conjugated bombesin analog was synthesized and radiolabeled with (6

44 It has been demonstrated that bombesin analogs can be radiolabeled with a variety of r

45 aim of this study was to develop 18F-labeled bombesin analogs for PET of GRPR expression in prostate

46 igopeptide to target angiogenesis and to use bombesin analogs to target the gastrin-releasing peptide

47 The study directly compares 64Cu bombesin analogs using the CB-TE2A and DOTA chelation sy

48 cantly improve the in vivo stability of 64Cu bombesin analogs.

49 at of the previously reported (64)Cu-labeled bombesin analogs.

50 cancer imaging and therapy with radiolabeled bombesin analogs.

51 and evaluate the imaging properties, of the bombesin analogue BAY 864367 for PET/CT in a small group

52 l trial with BAY 864367, a new (18)F-labeled bombesin analogue.

53 carbocyanine derivatives of somatostatin and bombesin analogues retained high binding for their respe

54 (64)Cu-NOTA-RGD-bombesin and (64)Cu-DOTA-RGD-bombesin had comparable dua

55 c-Myc, a Src target gene, to be activated by bombesin and a potential coactivator of AR-mediated acti

56 Picomolar concentrations of bombesin and CCK evoked similar patterns of cytosolic Ca

57 Bombesin and cholecystokinin (CCK) peptides act as signa

58 NEP substrates such as bombesin and endothelin-1 induce cell migration.

59 The neuropeptides bombesin and endothelin-1 stimulate prostate cancer (PC)

60 inactivation of its neuropeptide substrates (bombesin and endothelin-1), which in the absence of NEP

61 he biological effects and signal pathways of bombesin and NT on LNCaP, a prostate cancer cell line wh

62 ther the G protein-coupled receptor agonists bombesin and vasopressin or the biologically active phor

63 ) in response to the mitogenic GPCR agonists bombesin and vasopressin.

64 It was previously shown that bombesin and/or neurotensin (NT) acts as a survival and

65 A peptide modulator of splicing (bombesin) and SRp expression vectors were used to modula

66 d with those of (64)Cu-NOTA-RGD, (64)Cu-NOTA-bombesin, and (64)Cu-DOTA-RGD-bombesin.

67 acetate, prostate-specific membrane antigen, bombesin, and amino acids.

68 cline-repressive expression system inhibited bombesin- and endothelin-1-stimulated FAK phosphorylatio

69 tribution, and radiation dosimetry of (68)Ga-bombesin antagonist (68)Ga-DOTA-4-amino-1-carboxymethylp

70 nt FAK Tyr-397 phosphorylation stimulated by bombesin at a concentration (10 micrometer) that suppres

71 peptide receptor targeting via radiolabeled bombesin-based peptides.

72 The bombesin-based pseudopeptide DOTA-4-amino-1-carboxymethy

73 We describe a new radiolabeled bombesin (BBN) analog for imaging and systemic radiother

74 Both bombesin (BBN) analogs and cyclic RGD peptides have been

75 Novel bombesin (BBN) antagonists were synthesized by coupling

76 Bombesin (BBN) has been known to bind to GRP receptors w

77 labeled analogs of the frog tetradecapeptide bombesin (BBN) have been proposed for diagnosis and ther

78 Bombesin (BBN) is a neurotransmitter of 14 amino acids a

79 The peptide bombesin (BBN) is a peptide with high affinity for the g

80 ntisense oligonucleotide was conjugated to a bombesin (BBN) peptide, and its intracellular delivery w

81 Bombesin (BBN) peptides have demonstrated high affinity

82 Bombesin (BBN), a 14 amino acid peptide, is an analogue

83 Bombesin (BBN), a 14-amino acid peptide, has been shown

84 e analogs based on the frog tetradecapeptide bombesin (BBN).

85 SCLC cells secrete bombesin (BBS)-like neuropeptides that act as autocrine

86 a variety of peptide hormones, including the bombesin (BBS)-like peptide, gastrin-releasing peptide (

87 of MARCKS protein is important for PMA- and bombesin (BBS)-mediated NT secretion in BON cells.

88 Bombesin (BN) or gastrin-releasing peptide (GRP) can sti

89 ceptor mediating the action of the mammalian bombesin (Bn) peptide, gastrin-releasing peptide recepto

90 The orphan receptor, bombesin (Bn) receptor subtype 3 (BRS-3), shares high ho

91 Mammalian bombesin (BN) receptors are among those most frequently

92 Previous studies showed that antagonists of bombesin (BN)/gastrin-releasing peptide (GRP) inhibit th

93 ted the cells with several concentrations of bombesin (BN, a GRPr agonist) to activate a variable num

94 -response curves of DNA synthesis induced by bombesin, bradykinin, or vasopressin and markedly inhibi

95 id FAK phosphorylation at Ser-843 induced by bombesin, bradykinin, or vasopressin.

96 senger (e.g., cerulein, carbamylcholine, and bombesin) but not to those that use adenosine 3',5'-cycl

97 4 was induced by treatment with EGF, IL-6 or bombesin, but not by heregulin or Gas6.

98 CCK-8, carbachol, and bombesin, but not VIP/secretin, decreased c-Met.

99 Secretagogues (cerulein, carbachol, and bombesin) can induce protease activation in acinar cells

100 ion was found using other agonists including bombesin, carbachol, and cAMP.

101 ous desensitization of LPA response, whereas bombesin caused heterologous desensitization.

102 ether, the available evidence indicates that bombesin causes release of endogenous gastrin that activ

103 ert-butylphenylsilane building block and the bombesin congeners.

104 In the case of the phthalocyanine-bombesin conjugate, competition experiments confirm the

105 ve the tumor uptake of (18)F-labeled silicon-bombesin conjugates.

106 nfavorably to the pharmacokinetic profile of bombesin conjugates.

107 hormone-releasing hormone, somatostatin, and bombesin could be used for the therapy of ovarian cancer

108 of this study was to develop a camptothecin-bombesin (CPT-BN) conjugate that interacts with all clas

109 Bombesin decreased SRp20; increased SRp30c, SRp40 levels

110 hese findings represent a novel mechanism of bombesin-dependent stimulation of mitogenesis by regulat

111 H-L-M-NH(2) ((177)Lu-AMBA) is a radiolabeled bombesin derivative that is bound and internalized by ce

112 We have synthesized a NOTA-conjugated bombesin derivative, NOTA-8-Aoc-BBN(7-14)NH(2), to label

113 Yet binding studies using (125)I-Tyr(4)-bombesin detected functional receptors on only five of t

114 Second, bombesin diminished alveolarization in C57BL/6 (but not

115 Given that bombesin does not directly bind to the AR and is known t

116 ate all effects of GRP, but only part of the bombesin effect on alveolarization, suggesting that nove

117 The bombesin-elicited translocation of vesicular ARF6 was mi

118 Mutational analyses showed that bombesin-enhanced cyclin D1 transcription required the b

119 to the cyclin D1 promoter were essential for bombesin-enhanced cyclin D1 transcription.

120 athyroid hormone-related peptide, serotonin, bombesin, etc., are agonists for G-protein-coupled recep

121 ntrations selectively inhibited CCK, but not bombesin-evoked signals.

122 n pancreatic acinar cells, acetylcholine and bombesin exclusively select the ER Ca2+ store, whereas c

123 romedin B (NMB) is a mammalian member of the bombesin family of peptides closely related to GRP, but

124 The BB2 receptor subtype, of the bombesin family of receptors, has been shown to be highl

125 In striking contrast, neuropeptides of the bombesin family, including gastrin-releasing peptide and

126 htly lower than RGD for integrin binding and bombesin for GRPR binding.

127 eterodimers, we evaluated (64)Cu-labeled RGD-bombesin for PET imaging of tumors.

128 Normally, levels of mammalian bombesin (gastrin-releasing peptide [GRP]) drop postnata

129 Bombesin, gastrin-releasing peptide, NMB, and a bombesin

130 (GHRH) antagonists, JV-1-65 and JV-1-63, and bombesin/gastrin-releasing peptide (BN/GRP) antagonist R

131 The bombesin/gastrin-releasing peptide (GRP) family of neuro

132 n, released by activation of cholinergic and bombesin/gastrin-releasing peptide neurons, acts mainly

133 Bombesin/GRP can induce features of BPD, including inter

134 Our results indicate that antagonists of bombesin/GRP inhibit the growth of U-87MG glioblastomas

135 In contrast, dY-bombesin had a very poor potency for rat BRS-3 (EC(50) =

136 (64)Cu-NOTA-RGD-bombesin and (64)Cu-DOTA-RGD-bombesin had comparable dual integrin alpha(v)beta(3)- a

137 Bombesin had multiple effects on Day 14 lung, when alveo

138 cid, 8-Aoc = 8-aminooctanoic acid, and BBN = bombesin), having very high selectivity and affinity for

139 ly reported the ability of (18)F-labeled RGD-bombesin heterodimer to be used for dual integrin alpha(

140 The synergistic effect of RGD-bombesin heterodimers observed in this study also encour

141 c utility, such as gastrin-releasing peptide/bombesin in lung carcinomas.

142 novel receptors may mediate some effects of bombesin in newborn lung.

143 and (64)Cu-NOTA-bombesin, or (64)Cu-DOTA-RGD-bombesin in PC-3 prostate cancer.

144 Like somatostatin, both PMA and bombesin increased sst2A receptor phosphorylation within

145 We found that bombesin induced a rapidly reversible plasma membrane tr

146 First, bombesin induced alveolar myofibroblast proliferation an

147 Here, we found that bombesin induced human cyclin D1 expression on both mRNA

148 ceptor agonists, including angiotensin II or bombesin, induced rapid and persistent PKD1 phosphorylat

149 Bombesin-induced AR acetylation at the same motif KLKK o

150 Likewise, bombesin-induced AR activation is inhibited by the domin

151 Therefore, we examined bombesin-induced AR transactivation and PSA expression i

152 found inhibition of p300 expression reduced bombesin-induced AR transactivation and PSA expression.

153 ly, we found that Src kinase is critical for bombesin-induced AR-mediated activity and is required fo

154 These include bombesin-induced assembly of focal adhesions, formation

155 protein kinase (MAPK) pathway is involved in bombesin-induced cell proliferation in prostate cancer c

156 inant-negative Ras mutant, RasN17, abolished bombesin-induced cyclin D1 activation.

157 Taken together, bombesin-induced cyclin D1 expression in prostate cancer

158 Do novo protein synthesis was requisite for bombesin-induced cyclin D1 expression.

159 for the first time, we have finely resolved bombesin-induced cytosolic Ca2+ oscillations in single p

160 oncentration (10 micrometer) that suppressed bombesin-induced FAK Tyr-577 phosphorylation.

161 Bombesin-induced gastroprotection and gastrin release ar

162 itric oxide synthase inhibition also negates bombesin-induced gastroprotection as well as the ability

163 psaicin-sensitive afferent neurons abolishes bombesin-induced gastroprotection while cyclo-oxygenase

164 ocation and activation of PKD in response to bombesin-induced GPCR activation.

165 at bombesin-activated AR (a) is required for bombesin-induced growth of LNCaP cells, (b) has a transc

166 rs or PKCdelta siRNA significantly increased bombesin-induced p300 HAT activity suggesting that Src k

167 ence of 100 nM DHT, we next examined whether bombesin-induced p300 HAT activity would result in enhan

168 the potential signaling pathways involved in bombesin-induced p300 HAT activity, we examined Src and

169 kinase activity or Src kinase siRNA blocked bombesin-induced p300 HAT activity, whereas PKCdelta inh

170 in, or bombesin receptor antagonists blocked bombesin-induced p300 HAT activity.

171 The kinetics of bombesin-induced phospholipase D activation and LPA prod

172 rmore, these studies provide a new model for bombesin-induced Rac1 activation that involves ARF6-regu

173 ctivator of AR-mediated activity specific to bombesin-induced signaling.

174 timulation of quiescent Swiss 3T3 cells with bombesin induces a rapid increase in the formation of co

175 By contrast, bombesin injected i.c. at 0.2 or 0.6 pmol had no effect

176 Bombesin injected into the cisterna magna potently inhib

177 ng concentrations of p300 in the presence of bombesin into PC-3 cells resulted in a linear increase i

178 Bombesin is a 14-amino-acid amphibian peptide that binds

179 ted by dominant negative ARF6, implying that bombesin is a physiological trigger of ARF6 activation.

180 de secretion, recent evidence indicates that bombesin is a potent gastroprotective agent.

181 Bombesin is an endogenous gut peptide that is prominent

182 ted the hyperoxia-induced increases in urine bombesin-like peptide and numbers of neuroendocrine cell

183 ch was preceded by increased levels of urine bombesin-like peptide at 48 hours of age.

184 Utilizing urine bombesin-like peptide for screening might permit early t

185 ed pulmonary neuroendocrine cells containing bombesin-like peptide immunoreactivity occur in infants

186 A first urine bombesin-like peptide level greater than 20,000 pg/mg cr

187 ession analyses revealed that elevated urine bombesin-like peptide levels are associated with BPD (od

188 Thus, elevated bombesin-like peptide levels in these infants at 1-4 day

189 We hypothesized that elevated urine bombesin-like peptide levels precede BPD.

190 Urine bombesin-like peptide levels, determined by radioimmunoa

191 nical efficacy and potential side effects of bombesin-like peptide ligands.

192 the assay, the interaction of a FITC-labeled bombesin-like peptide with the gastrin-releasing peptide

193 Bombesin-like peptides (BLPs) are elevated in newborns w

194 In mammals, bombesin-like peptides mediate a broad range of physiolo

195 o studied, are similarly directly excited by bombesin-like peptides, the peptides may function to ini

196 l model for the development of modulators of bombesin-like receptor function, we undertook a search f

197 [Lys(3)]bombesin ([Lys(3)]BBN) was conjugated with 1,4,7,10-tetr

198 [Lys3]Bombesin ([Lys3]BBN) and aminocaproic acid-bombesin(7-14

199 e, for the first time, that stimulation with bombesin, lysophosphatidic acid, PDB, or EGF induces pho

200 focuses on 3 neuropeptide receptor systems (bombesin, neurotensin, and neuropeptide-Y) that offer hi

201 Therefore, we examine the effect of bombesin on p300 HAT activity.

202 odinated zinc phthalocyanine with acetylenic bombesin or arginine-glycine-aspartic acid (RGD) derivat

203 The present study tests whether exogenous bombesin or GRP given perinatally alters alveolar develo

204 in FAK phosphorylation at Ser-910 induced by bombesin or PDB but not by EGF.

205 ramatically activated by cell treatment with bombesin or PDBu as judged by in vitro kinase autophosph

206 os accumulation and DNA synthesis induced by bombesin or vasopressin in PKD-overexpressing cells.

207 lectively potentiates mitogenesis induced by bombesin or vasopressin in Swiss 3T3 cells by increasing

208 Furthermore, bombesin or vasopressin promoted a striking increase in

209 t completely PKC-dependent at later times of bombesin or vasopressin stimulation (20-90 min).

210 progression to DNA synthesis in response to bombesin or vasopressin through a pathway that requires

211 Addition of bombesin or vasopressin to Swiss 3T3 cells overexpressin

212 Bombesin or vehicle was injected into the medullary pare

213 e mixture of (64)Cu-NOTA-RGD and (64)Cu-NOTA-bombesin, or (64)Cu-DOTA-RGD-bombesin in PC-3 prostate c

214 n with neutral endopeptidase, which degrades bombesin, or bombesin receptor antagonists blocked bombe

215 sphorylation were induced by phorbol esters, bombesin, or cross-linking of B lymphocyte antigen recep

216 At 4 h after the addition of bombesin, p300 HAT activity increased 2.0-fold (P<0.01).

217 gation of dyes to truncated somatostatin and bombesin peptide analogues results in promising diagnost

218 ral backbone-modified analogs of the studied bombesin peptide bearing multiple triazole substitutions

219 The mammalian bombesin peptides [gastrin-releasing peptide (GRP) and n

220 Radiolabeled RGD and bombesin peptides have been extensively investigated for

221 orescein to the alpha-amino lysine linker of bombesin peptides resulted in high receptor binding.

222 molecules in rats bearing somatostatin- and bombesin-positive tumors showed selective uptake of the

223 (64)Cu-NOTA-RGD-bombesin possessed significantly higher tumor uptake tha

224 to I(310)F(311) had little effect on the dY-bombesin potency.

225 Stimulation of Swiss 3T3 cells with bombesin promoted a striking increase ( approximately 13

226 irculating intact somatostatin, gastrin, and bombesin radiopeptides in mouse models, resulting in a r

227 -His-Sta-Leu-NH2 ((68)Ga-RM2) is a synthetic bombesin receptor antagonist that targets gastrin-releas

228 -His-Sta-Leu-NH2 ((68)Ga-RM2) is a synthetic bombesin receptor antagonist that targets gastrin-releas

229 l endopeptidase, which degrades bombesin, or bombesin receptor antagonists blocked bombesin-induced p

230 to purified G protein alpha subunits by the bombesin receptor family, including gastrin-releasing pe

231 the binding affinity of each peptide for the bombesin receptor site was determined.

232 both Galpha(q) and Galpha(13) in response to bombesin receptor stimulation.

233 lso attenuated PKD activation in response to bombesin receptor stimulation.

234 mediates PKD activation in response to acute bombesin receptor stimulation.

235 (GRP-R), neuromedin B receptor (NMB-R), and bombesin receptor subtype 3 (BRS-3).

236 ne expression, and identified mRNAs encoding bombesin receptor subtype 3 and neuromedin-B receptor (N

237 Neuromedin B (NMB) receptor-null and bombesin receptor subtype 3-null mice had the same respo

238 besin, gastrin-releasing peptide, NMB, and a bombesin receptor subtype 3-specific ligand induced mast

239 We cloned the gene and cDNA for rat bombesin receptor subtype-3 (BRS-3) and characterized it

240 Bombesin receptor subtype-3 (BRS-3) is an orphan G-prote

241 lish a contiguous signaling pathway from the bombesin receptor to ROCK in PC cells, and they implicat

242 ombesin, whereas neither NMB nor a synthetic bombesin receptor type 3 ligand had any effect.

243 a selective agonist for the BB(2) subtype of bombesin receptor, is reported to depolarise GABAergic i

244 in and carbocyanine dyes to somatostatin and bombesin receptor-avid peptides and examined their recep

245 vation in response to agonist stimulation of bombesin receptor.

246 vation in response to agonist stimulation of bombesin receptor.

247 astrin-releasing peptide-preferring, and the bombesin-receptor subtype 3.

248 t the expression of the previously described bombesin-receptor subtype 4 is limited to amphibians.

249 subtype 3 (BRS-3), shares high homology with bombesin receptors (neuromedin B receptor (NMB-R) and ga

250 and leukemia-associated RhoGEF (LARG), link bombesin receptors to RhoA in a non-redundant manner in

251 Upon stimulation of the bombesin receptors, KUZ increases the docking and activa

252 4, encoding a receptor related to vertebrate bombesin receptors, responds specifically to allatostati

253 Bombesin-related peptides reduced input resistance and d

254 d the expression profiles of the three known bombesin-related receptors.

255 th either phorbol 12-myristate 13-acetate or bombesin, respectively.

256 Compared with other tracers, (64)Cu-NOTA-RGD-bombesin showed favorable in vivo kinetics and enhanced

257 ific kinase inhibitors together with ET-1 or bombesin showed that IGF-IR activation is required for n

258 s revealed that the M3, cholecystokinin, and bombesin signaling complexes at the apical pole are much

259 mined Src and PKCdelta pathways that mediate bombesin signaling.

260 ke the peptides, DTP had no affinity for the bombesin site, thereby suggesting that DTP is displaying

261 se data show that the neuropeptides ET-1 and bombesin stimulate ligand-independent activation of the

262 ting Ack1 downstream), interleukin (IL)-6 or bombesin stimulated cell proliferation in the absence of

263 The PKC inhibitor GF109203X blocked PMA- and bombesin- stimulated sst2A phosphorylation, whereas stim

264 We demonstrate that bombesin-stimulated PC cell migration occurs via the het

265 tivates PDZ-RhoGEF and LARG, is required for bombesin-stimulated RhoA activation.

266 ion was greatly diminished at later times of bombesin stimulation (e.g. 45 min).

267 ofoundly inhibited PKD activation induced by bombesin stimulation for <15 min but did not prevent PKD

268 prevent PKD catalytic activation induced by bombesin stimulation for longer times (>60 min).

269 Bombesin stimulation of COX-2 expression requires an inc

270 ed rapid (1-5-min) PKD activation induced by bombesin stimulation, but this inhibition was greatly di

271 urther studies showed Egr-1 was induced upon bombesin stimulation.

272 operties of AR activated by the neuropeptide bombesin that distinguish it from androgen-activated AR.

273 uptake than did (64)Cu-NOTA-RGD, (64)Cu-NOTA-bombesin, the mixture of (64)Cu-NOTA-RGD and (64)Cu-NOTA

274 PC-3 prostate cancer cells and (125)I-Tyr(4)-bombesin to determine the inhibitory concentration of 50

275 d gastroprotection as well as the ability of bombesin to increase gastric mucosal blood flow.

276 genous somatostatin increases the ability of bombesin to prevent gastric injury by increasing gastrin

277 This review article examines the ability of bombesin to prevent gastric injury.

278 BAY 864367, a novel (18)F-labeled bombesin tracer, was successfully investigated in a firs

279 ntestinal activity accumulation than did the bombesin tracers.

280 s present at nanomolar levels in medium from bombesin-treated cells.

281 Compared with wild-type littermates, bombesin-treated GRP receptor (GRPR)-null mice had incre

282 phosphorylation at Tyr-267, whereas IL-6 or bombesin treatment did not.

283 Western analyses revealed ET-1 and bombesin treatment induced phosphorylation of IGF-IRbeta

284 mice accumulated fewer lung mast cells after bombesin treatment.

285 that the G-protein-coupled receptor agonist bombesin triggers the redistribution of ARF6- and Rac1-c

286 with the G protein-coupled receptor agonists bombesin, vasopressin, or bradykinin induced an extremel

287 lectively potentiates mitogenesis induced by bombesin, vasopressin, or PDBu in Swiss 3T3 cells.

288 Addition of bombesin, vasopressin, or PDBu to cultures of Swiss 3T3

289 Together these results demonstrate that bombesin, via Src and PKCdelta signaling pathways, activ

290 determine whether BLPs are proinflammatory, bombesin was administered intratracheally to mice.

291 ctivation in response to either Galpha(q) or bombesin was completely prevented by mutation of Ser(744

292 RGD-bombesin was coupled with 1,4,7,10-tetraazacyclododecane

293 horylation of Ser(910) by ERK in response to bombesin was increased by FAT opening.

294 d in vivo characteristics of (64)Cu-NOTA-RGD-bombesin were compared with those of (64)Cu-NOTA-RGD, (6

295 analogs based on the tumor targeting peptide bombesin were synthesized and fully evaluated in vitro a

296 GRP had the same effects as bombesin, whereas neither NMB nor a synthetic bombesin r

297 es the neuropeptides endothelin-1 (ET-1) and bombesin, which are implicated in progression to androge

298 Stimulation of cells with bombesin, which evokes [Ca(2+)](c) oscillations indistin

299 RB3-E3 bound dY-bombesin with high affinity (K(i) = 1.2 +/- 0.7 nM), and

300 ) = 1.2 +/- 0.7 nM), and was activated by dY-bombesin with high potency (EC(50) = 1.8 +/- 0.5 nM).